Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease
A 45-year-old male patient was diagnosed with bilateral RCC five years ago and subsequently underwent partial left nephrectomy and radical right nephrectomy. Pathology of the samples revealed clear cell RCC in both kidneys. At this time, the patient was found to have multiple pancreatic cysts and was diagnosed with RCC and VHL disease. At three months post-operative follow-up, the patient was admitted to the hospital with right flank pain. Abdominal CT scan showed a recurrent RCC measuring 2.5 cm in size in the right psoas muscle adjoining the partially nephrectomized kidney. The patient started on sunitinib treatment (50 mg, four-week treatment with a two-week rest period). Treatment with sunitinib resulted in regression of the tumor, and at six months, the patient had achieved a partial response (). At 21 months, the patient is still undergoing treatment with sunitinib and is being followed up.